Betalains for Health & Longevity

Evidence Review created on 09/20/2026 using AI4L / Opus 5

Also known as: Betalain, Betacyanins, Betaxanthins, Betanin, Betanidin, Isobetanin, Indicaxanthin, Vulgaxanthin, Beetroot Red, E162

Motivation

Betalains are the water-soluble pigments that give beetroot its deep red color, prickly pear its crimson or golden flesh, and red dragon fruit its magenta pulp. They belong to a small plant family that uses them instead of the more familiar blue-red pigments found in berries. Two groups exist: the red-violet betacyanins, of which betanin is the best known, and the yellow-orange betaxanthins. Interest in them rests on laboratory work showing that they neutralize reactive molecules and quieten inflammatory signaling inside cells.

Beetroot has been eaten and used medicinally for centuries, and beet-derived red has been an approved food coloring for decades, so human exposure is long-standing and broad. More recently, manufacturers have stripped the sugars and nitrates out of beetroot to produce concentrated betalain capsules, allowing the pigments to be tested on their own rather than as one ingredient among many in beetroot juice.

This review examines what is known about betalains taken deliberately, in food or concentrated form, by adults focused on long-term health: the mechanisms proposed for them, the human and laboratory evidence for benefit, the risks and unknowns, and the practical questions of dose, timing, sourcing and monitoring.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Betalain

Covers the tyrosine-derived biosynthesis, the betacyanin and betaxanthin split, and the distribution of these pigments across the Caryophyllales order, giving the botanical and chemical context the health literature assumes.

Examine

Betalains

Examine’s dedicated entry defines betalains as the pigments replacing anthocyanins in certain fruits, names beetroot as the major dietary source, and flags the red urine tint; its research breakdown is archived.

ConsumerLab

No ConsumerLab article exists for betalains. Direct searches of consumerlab.com for both “betalain” and “betalains” returned no results.

Systematic Reviews

Systematic reviews covering betalain effects on vascular, metabolic and cancer endpoints, and the evidence certainty behind them.

The effects of betalain-rich cacti (dragon fruit and cactus pear) on endothelial and vascular function: a systematic review of animal and human studies - Cheok et al., 2020

Sixteen studies, only seven in humans; animal vasodilation and blood-pressure signals were not matched by robust human intervention data.
Antidiabetic and Anti-Obesity Effects of Betalains: A Systematic Review of Preclinical Evidence - Noman et al., 2026

Twelve preclinical studies; consistent glucose, insulin-resistance and lipid improvements, with the authors stating that no clinical trials confirm them.
Anticancer and Anti-Inflammatory Potential of Betalains: A Systematic Review on Preclinical Studies - Fatima et al., 2026

Twenty-five cell and animal studies; cell-death induction and inflammatory-switch suppression are reproducible in vitro but untested in humans.
Should We ‘Eat a Rainbow’? An Umbrella Review of the Health Effects of Colorful Bioactive Pigments in Fruits and Vegetables - Blumfield et al., 2022

Places betalains against carotenoids, flavonoids and chlorophylls across 449 meta-analyzed outcomes; certainty was very low to low for most.

Coverage of the trade-off: the four reviews above all address claimed benefits. No systematic review or meta-analysis addresses betalain safety, adverse effects, oxalate burden or cost, so the risk side of the trade-off is unrepresented in the systematic-review literature.

Mechanism of Action

Betalains share a betalamic acid core. A cyclo-DOPA unit (an oxidized form of the amino acid tyrosine) yields the red-violet betacyanins, betanin chief among them; an amino acid or amine yields the yellow-orange betaxanthins such as indicaxanthin (Sadowska-Bartosz & Bartosz, 2021).

Three actions are proposed. First, direct radical scavenging: phenolic and cyclic amine groups donate electrons and protons readily, and betalains inside low-density lipoprotein particles make them resistant to oxidation (Tesoriere et al., 2004). Second, induction of the body’s own defenses: betanin moves Nrf2 (a master switch for protective genes) into the nucleus of human liver cells and raises glutathione S-transferase and NQO1 (two detoxifying enzymes) (Krajka-Kuźniak et al., 2013). Third, suppression of NF-κB (a central inflammatory switch), lowering TNF-α (tumor necrosis factor alpha, an inflammation driver), IL-6 (interleukin-6, an inflammatory messenger) and the inflammation-driving enzymes COX-2 (cyclooxygenase-2) and iNOS (inducible nitric oxide synthase) in preclinical models (Fatima et al., 2026).

They are multi-target, not selective, with no identified receptor. Betanin’s plasma half-life is 0.94 hours against 2.36 hours for indicaxanthin, both cleared by 12 hours (Tesoriere et al., 2004); indicaxanthin crosses the blood-brain barrier into cortex, hippocampus and cerebellum (Gambino et al., 2018). Gastric acid and colonic bacteria break them down, not liver enzymes (Watts et al., 1993).

A competing reading holds systemic exposure too low for blood scavenging to matter: only 0.28% of ingested betanin is recovered intact in urine (Frank et al., 2005). On that view any effect is signaling-mediated or driven by colonic metabolites.

Historical Context & Evolution

Beetroot has been cultivated since antiquity, first for its leaves and only later for the swollen root, whose red juice was used in folk practice for blood and liver complaints. The pigments themselves were chemically resolved only in the 1960s, when the betalamic acid core and the betanin structure were established and the class was named for the beet genus Beta (Sadowska-Bartosz & Bartosz, 2021).

Two separate paths then led to the current interest. One was regulatory: beet red was approved as a food colorant, which created decades of broad, uncontroversial human exposure and an industrial supply of purified pigment. The other was physiological: the Palermo group showed in the early 2000s that dietary betalains are absorbed, appear in plasma, and are incorporated into low-density lipoprotein particles, where they resist oxidation — the first evidence that these pigments do something in people rather than merely color food (Tesoriere et al., 2004).

Sports science added a twist. Beetroot juice had been shown to improve endurance, and the effect was attributed to its nitrate content. Removing the nitrate and sugar left a betalain-only concentrate, and trials of that concentrate still found performance gains (Van Hoorebeke et al., 2016). That concentrate is supplied by a single manufacturer, which funded or partnered on the trials of it, so this evidence is not independent of the party selling the product. Whether the earlier beetroot-juice results were partly pigment-driven remains open, because the nitrate-depleted juice used as the control in those studies still contained betalains.

Expected Benefits

High 🟩 🟩 🟩

Endurance Exercise Performance and Recovery

Nitrate- and sugar-free betalain concentrate improved time-trial performance in three crossovers: 5-km time fell 36 seconds, 2.6% faster (Van Hoorebeke et al., 2016); 10-km time fell 50.8 to 49.5 minutes with a smaller rise in creatine kinase (an enzyme released when muscle fibers are damaged) (Montenegro et al., 2017); 30-minute cycling power rose 225.3 to 231.6 watts (Mumford et al., 2018). A fourth found no gain in running economy or oxygen uptake (Vitti et al., 2025). All four were small, 13 to 28 trained adults, using one manufacturer’s product.

Magnitude: 5-km running time trial 36 seconds faster (23.0 versus 23.6 minutes, roughly 2.6%); 10-km time trial 1.3 minutes faster (49.5 versus 50.8 minutes); 30-minute cycling average power +6.3 watts (231.6 versus 225.3 W, roughly 2.8%).

Medium 🟩 🟩

Endothelial Function and Arterial Stiffness

In a double-blind crossover trial, 24 g of red-fleshed dragon fruit powder supplying 33 mg betalains raised flow-mediated dilation (an ultrasound measure of how well an artery widens, validated against cardiovascular outcomes) by 1.3 percentage points both acutely and after 14 days, and reduced augmentation index (a marker of arterial stiffness) by 7.0 points (Cheok et al., 2022). Eighteen healthy young adults completed it; blood pressure did not change, and no second trial has replicated the result.

Magnitude: Flow-mediated dilation +1.3 ± 0.2 percentage points at 14 days and +1.3 ± 0.4 at 4 hours; pulse-wave velocity (the speed at which the pulse travels along an artery, a second stiffness measure) −0.5 ± 0.2 m/s at 3 hours; augmentation index −7.0 ± 3.3 percentage points at 14 days.

Atherogenic Lipids and Homocysteine

Two weeks of a betalain-rich beetroot supplement or a betacyanin-rich Opuntia stricta supplement lowered total cholesterol, triglycerides and low-density lipoprotein cholesterol in 48 men with established coronary artery disease, with the investigators judging only the homocysteine (an amino acid linked to vascular damage), low-density lipoprotein and non-high-density lipoprotein cholesterol changes clinically meaningful (Rahimi et al., 2019). This is a single pilot crossover in a diseased population, not a healthy one.

Magnitude: Direction is downward for total cholesterol, triglycerides, low-density lipoprotein and homocysteine, holding in men with established coronary artery disease supplemented for two weeks; the published report gives no effect-size figure for these outcomes.

Glycemic Markers

Fasting glucose fell alongside lipids in the two-week coronary-disease crossover, though investigators did not call the change clinically meaningful (Rahimi et al., 2019). Remaining support is preclinical: twelve cell and animal studies reported lower glucose and insulin resistance (Noman et al., 2026). No trial has tested glycated hemoglobin.

Magnitude: Direction is downward for fasting glucose in men with coronary artery disease over two weeks; the published report gives no effect-size figure, and no controlled trial has measured glycated hemoglobin.

Low 🟩

Blood Pressure Reduction ⚠️ Conflicted

Betalain supplements lowered systolic and diastolic pressure in coronary patients (Rahimi et al., 2019), but dragon-fruit betalains left pressure unchanged in healthy adults (Cheok et al., 2022). Net reading: any pressure effect looks confined to people whose pressure or vascular health is already impaired.

Magnitude: Direction is downward, holding only in men with established coronary artery disease and absent in healthy adults; the published reports give no millimetre-of-mercury figure for the change.

Reduction of Inflammatory Signaling ⚠️ Conflicted

Betalain concentrate did not change interleukin-6 or tumor necrosis factor alpha around a cycling time trial (Mumford et al., 2018), while preclinical work suppresses these mediators (Fatima et al., 2026). Net reading: the effect is reproducible in cells and animals but absent in the blood of exercising adults.

Magnitude: Not quantified in available studies. The only controlled human cytokine measurement found no change, so no effect size exists to report.

Autonomic Balance and Heart-Rate Variability ⚠️ Conflicted

Cactus pear juice raised heart-rate variability (beat-to-beat variation reflecting nervous-system control of the heart) after exercise in eight women (Bellafiore et al., 2021), while the same juice taken with a fatty meal lowered it in seventeen men (Gouws et al., 2022). Net reading: direction tracks the setting, not the pigment.

Magnitude: Direction is upward after exercise and downward after a high-fat meal, in two small crossovers of whole-fruit juice; neither report gives an effect-size figure for the change.

Speculative 🟨

Systemic Oxidative-Stress Reduction

Two weeks of cactus pear fruit cut plasma 8-epi-prostaglandin F2-alpha and malondialdehyde and halved low-density lipoprotein hydroperoxides in 18 healthy adults (Tesoriere et al., 2004). These are unvalidated oxidation markers, not clinical outcomes.

Longevity-Pathway Activation

Four pure betalains extended Caenorhabditis elegans lifespan by up to 16.8% via DAF-16/FOXO and SKN-1/Nrf2 (stress-resistance transcription factors) (Guerrero-Rubio et al., 2020). No mammalian or human lifespan data exist.

Anticancer Activity

Betalains cut colorectal cancer cell viability at 64–107 µg/mL, induced programmed cell death and stalled lung cancer cell division across 25 preclinical studies (Fatima et al., 2026). No human cancer trial exists.

Neuroprotection

Indicaxanthin crosses the blood-brain barrier and accumulates in cortex and hippocampus, damping nerve-cell firing in rats (Gambino et al., 2018). Red-beet pigments separately delayed amyloid-driven paralysis in worms (Imamura et al., 2022).

Body-Fat Reduction

Betalains cut triglyceride accumulation in fat cells and damped the genes that build new fat across twelve preclinical studies (Noman et al., 2026). No human trial has measured body weight or fat mass.

Liver Protection

Betanin raised detoxifying enzymes in human liver cells via Nrf2 (Krajka-Kuźniak et al., 2013) and blunted paracetamol- and diclofenac-induced liver injury in rats (Motawi et al., 2020). No human liver outcome exists.

Antimicrobial Activity

Betalain extracts inhibit a broad range of bacteria, including multidrug-resistant strains, in minimum-inhibitory-concentration assays (Martinez et al., 2024). No human infection outcome has been studied.

Benefit-Modifying Factors

Genetic and trait variation in pigment survival: No validated pharmacogenetic variant is known. The beeturia trait (red urine after beet intake) tracks gastric acidity and colonic conditions rather than a characterized polymorphism (Watts et al., 1993), and higher intact excretion may mark higher absorption.
Baseline biomarker levels: The clearest lipid and homocysteine responses appeared in men whose values were already abnormal from coronary disease (Rahimi et al., 2019), while healthy adults with normal pressure showed no pressure change (Cheok et al., 2022).
Sex-based differences: Trials enrolled both sexes — 9 men and 13 women in the triathlete study (Montenegro et al., 2017) — but none reported sex-stratified results, so a sex difference in benefit has been neither established nor excluded.
Pre-existing health conditions: Coronary artery disease, disordered blood fats and elevated homocysteine define the population in which measurable marker changes occurred. In healthy athletes the only reliable change was performance, not any blood marker.
Age-related considerations: Benefit was shown in trained adults aged 18–40; the 40–65 range with overweight was tested in a completed trial whose results remain unpublished (NCT06117007). Older adults with stiffer arteries have more room for vascular endpoints to move.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Beeturia and Red-Pigmented Urine or Stool

Betacyanins that survive the stomach and colon are excreted unchanged, coloring urine and stool pink to red. Across 100 adults given 60 mg beetroot extract, four produced visibly red urine (Watts et al., 1993); the classical prevalence estimate is 10–14%, rising when colonic oxalic acid protects the pigment from being decolorized (Eastwood & Nyhlin, 1995). The effect is harmless but is routinely mistaken for blood, and it is more frequent in iron deficiency (Tunnessen et al., 1969).

Magnitude: 4 of 100 adults (4%) produced visibly red urine after a single 60 mg beetroot extract dose; the classical population estimate is 10–14%, with urinary recovery of intact betacyanins ranging 0.06–0.6% of the dose.

Medium 🟥 🟥

No risk reaches Medium: apart from pigment excretion, no adverse outcome has been measured in a controlled human trial, and the single blood-pressure signal that exists is contradicted by a second trial.

Low 🟥

Additive Blood-Pressure Lowering ⚠️ Conflicted

Betalain supplements lowered blood pressure in men with coronary artery disease (Rahimi et al., 2019), but left it unchanged in healthy adults (Cheok et al., 2022). Stacked on antihypertensive drugs or nitrates, any further fall can cause lightheadedness on standing. Net reading: the hypotensive exposure is confined to medicated users.

Magnitude: Direction is downward for both systolic and diastolic pressure, holding in men with coronary artery disease over two weeks and absent in healthy adults; the published report gives no millimetre-of-mercury figure.

Oxalate Burden from Whole-Food Sources

Betalain-rich leaves carry high oxalate: silver beet (Swiss chard) measured 4,276 mg per 100 g fresh weight (Wadamori et al., 2014), and oxalate is the main constituent of most kidney stones (Chai & Liebman, 2005). The burden belongs to the food, not the pigment; concentrates are essentially oxalate-free.

Magnitude: Swiss chard leaves 4,276 mg total oxalate per 100 g fresh weight; boiling removes 30–87% of the soluble fraction, and roughly 75% of kidney stones are primarily calcium oxalate.

Nitrate Co-Exposure from Beetroot Vehicles

Most people obtain betalains from beetroot juice, which also delivers inorganic nitrate — 400 mg per 70 mL of concentrate (Heredia-Martinez et al., 2022). Nitrate widens blood vessels independently of the pigments (Milton-Laskibar et al., 2021), so juice-based intake carries a hypotensive exposure that nitrate-depleted concentrate does not.

Magnitude: 400 mg inorganic nitrate per 70 mL of concentrated beetroot juice, against 0 mg in nitrate-depleted betalain concentrate; in that study blood pressure and plasma potassium did not change and no adverse events occurred.

Allergic Reactions

Anaphylaxis (a rapid, whole-body allergic reaction) has been reported after beetroot ingestion alongside beeturia (Luke & Watson, 1963). Whether the pigment or another beet protein is the allergen is unestablished, and the evidence is a single old case description rather than a series.

Magnitude: Not quantified in available studies. Only isolated case reports exist, so no incidence rate has been established for betalain-containing preparations.

Speculative 🟨

Interference with Drug-Metabolizing Enzymes

Betanin raised glutathione S-transferase and NQO1 (enzymes that neutralize and clear toxins) in human liver cells via Nrf2 (Krajka-Kuźniak et al., 2013). Whether this alters clearance of co-administered drugs is untested in people.

Unknown Long-Term Safety at Concentrated Doses

Human trials run 2–4 weeks at most. Acute rodent work found no deaths at 5 g/kg of cactus betalain pigment (Reynoso et al., 1999), but no chronic or reproductive toxicity study has been published.

Hepatic Metal Accumulation from Whole-Beet Loading

Rats fed freeze-dried table beet accumulated copper, iron, zinc and manganese in the liver (Blázovics et al., 2007). The basis is that single rodent study; the load tracks the vegetable’s minerals, not the pigment.

Risk-Modifying Factors

Gastric acidity and acid-suppressing therapy: Betacyanins are destroyed by gastric acid; a raised stomach pH lets more intact pigment reach the colon (Watts et al., 1993). Beeturia is correspondingly more common among proton pump inhibitor (acid-blocking medication) users.
Baseline iron status: Beeturia is more frequent in iron deficiency (Tunnessen et al., 1969) and has been raised as a marker in iron overload (Sotos, 1999), making pigment appearance an unreliable guide to absorbed dose.
Sex-based differences: No sex-specific adverse pattern has been reported. The prevalence work on beeturia pooled men and women without stratifying results (Watts et al., 1993), so any difference remains unmeasured.
Genetic polymorphisms: No variant affecting betalain transport, metabolism or toxicity has been identified. The older literature framed beeturia as a possible polymorphism, but the excretion distribution proved unimodal (Watts et al., 1993).
Pre-existing health conditions: Calcium oxalate stone disease, high urinary oxalate and reduced kidney function raise the stakes of oxalate-rich whole-food sources; treated hypotension and coronary disease raise the stakes of additive pressure lowering.
Age-related considerations: Older adults more often use acid suppressants and antihypertensives and have less kidney reserve, which amplifies the beeturia and oxalate considerations rather than introducing new ones.

Key Interactions & Contraindications

Antihypertensive drugs: Angiotensin-converting enzyme inhibitors (lisinopril, ramipril), angiotensin receptor blockers (losartan, valsartan) and calcium channel blockers (amlodipine). Caution — additive pressure fall with lightheadedness. Home pressure logging through the first four weeks is the practical check.
Organic nitrates and PDE5 inhibitors: Isosorbide mononitrate, nitroglycerin, sildenafil, tadalafil (PDE5 is phosphodiesterase type 5, the enzyme blocked by erectile-dysfunction drugs). Absolute contraindication with nitrate-containing beetroot juice — severe hypotension. Mitigation is a nitrate-depleted preparation.
Glucose-lowering drugs: Metformin, sulfonylureas (glipizide, glibenclamide) and SGLT2 inhibitors (sodium-glucose cotransporter 2 inhibitors, which flush glucose into urine; empagliflozin). Monitor — modest additive glucose lowering; more frequent self-monitoring through the first month.
Antiplatelet and anticoagulant drugs: Aspirin, clopidogrel, warfarin, apixaban. Caution — betalains are among the phytochemicals shown to modulate platelet signaling in laboratory work (Tamer et al., 2022). No human bleeding events are reported; bruising is the marker to watch.
Over-the-counter medications: Proton pump inhibitors (omeprazole) and H2 blockers (famotidine) raise gastric pH and increase red-urine frequency — cosmetic only. Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen) overlap the proposed anti-inflammatory action with no documented interaction.
Supplement interactions: Nitric-oxide precursors (L-Citrulline, L-Arginine) and other pressure-lowering supplements (hibiscus, magnesium, potassium) add to the hypotensive effect — monitor, with lightheadedness the signal. Calcium taken with oxalate-rich beet greens binds oxalate in the gut, reducing absorption.
Other intervention interactions: Chronic high-dose antioxidant supplementation (vitamin C above 1 g, vitamin E above 400 IU) around training may blunt adaptation. Caution applies to the stack, not the pigment, since trial betalain doses are far smaller.
Populations who should avoid betalains:
- Recurrent calcium oxalate stone formers using whole-food sources (beet greens, Swiss chard) rather than purified concentrate, particularly with 24-hour urinary oxalate above 40 mg
- Anyone with documented beet or Amaranthaceae allergy, given the reported anaphylaxis (Luke & Watson, 1963)
- People with symptomatic hypotension (seated systolic below 100 mmHg) or on three or more antihypertensive agents
- Chronic kidney disease stage 4–5 (estimated glomerular filtration rate below 30 mL/min/1.73 m²) using oxalate-rich whole-food sources
- Pregnancy and lactation at concentrate doses, since no reproductive toxicity data exist at any dose
- Metal-accumulating disease (hemochromatosis, Wilson disease and porphyria cutanea tarda — inherited disorders in which iron or copper builds up in tissue) at high whole-beet intakes, given the liver metal loading seen in rodents (Blázovics et al., 2007)

Risk Mitigation Strategies

Nitrate-depleted concentrate over juice: Removes the 400 mg nitrate load per 70 mL serving that drives the hypotension risk while keeping the pigment; this is the preparation used in every betalain-specific performance trial (Van Hoorebeke et al., 2016).
Baseline urinalysis before the first dose: A clean dipstick on file prevents pink urine from triggering a workup for blood in urine; beeturia affects roughly 10–14% of people (Eastwood & Nyhlin, 1995).
Four weeks of home blood-pressure logging: Twice-daily seated readings catch additive hypotension in anyone already on pressure-lowering drugs, the group in whom the fall was actually measured (Rahimi et al., 2019).
Capped whole-leaf intake in stone formers: Keeping Swiss chard and beet greens under one cooked cup daily, and boiling rather than steaming, removes 30–87% of soluble oxalate and the stone risk it carries (Chai & Liebman, 2005).
Calcium alongside oxalate-rich meals: 300–500 mg of calcium eaten alongside beet greens binds oxalate inside the gut, lowering the fraction absorbed and therefore the calcium oxalate stone risk.
Dose timing away from acid suppressants: Dosing when gastric pH is lower degrades more pigment before the colon, reducing the beeturia that is otherwise mistaken for bleeding (Watts et al., 1993).
Lipid and homocysteine re-check at 8–12 weeks: Confirms the marker change that motivated use and prevents indefinite continuation of an intervention that is moving nothing measurable.

Therapeutic Protocol

Standard concentrate protocol: 100 mg betalain-rich beetroot concentrate daily as two 50 mg capsules, roughly 25 mg betalains, for six days, then 50 mg taken 120–150 minutes before the target session (Van Hoorebeke et al., 2016).
Vascular protocol: One daily capsule supplying 25 mg betalains for 28 days is the regimen used in the completed arterial-endpoint trial (NCT06117007); the published dragon-fruit trial used 33 mg daily for 14 days (Cheok et al., 2022).
Whole-food alternative: Roughly 85 g of beetroot supplies about 100 mg betalains, several times the concentrate dose, but adds sugar, nitrate and oxalate to the exposure (Van Hoorebeke et al., 2016).
Competing approaches: Sports practice favors nitrate-depleted concentrate; cardiometabolic practice favors whole beetroot or dragon fruit. Neither has been tested against the other, and the two deliver different companion compounds alongside the same pigment.
Origin of each approach: The concentrate protocol comes from the University of California Davis Sports Performance Laboratory (Montenegro et al., 2017); the dietary-dose vascular work comes from the King’s College London nutrition group (Cheok et al., 2022).
Best time of day: Trials dosed before breakfast and before dinner during loading, then 2–2.5 hours before exercise, timing chosen to coincide with the 3-hour plasma peak (Tesoriere et al., 2004).
Half-life in the body: Betanin’s plasma half-life is 0.94 hours and indicaxanthin’s 2.36 hours, with both cleared by 12 hours (Tesoriere et al., 2004) — short enough that accumulation does not occur.
Split versus single dosing: Loading used twice-daily 50 mg doses; the pre-exercise dose was single. The short half-lives favor splitting when the aim is sustained exposure and a single dose when the aim is a pre-exercise peak.
Genetic considerations: No pharmacogenetically relevant variant has been identified. MTHFR variants (which slow folate processing and raise homocysteine) mark the group whose homocysteine has most room to fall, but this has not been tested.
Sex-based differences: Trials enrolled both sexes without stratified analysis (Montenegro et al., 2017). No dose adjustment by sex has been proposed or tested in any betalain study.
Age-related considerations: Published trials used 18–40-year-olds; the 40–65 range with overweight was covered by a completed trial whose results are unpublished (NCT06117007). No age-specific dose has been established at either end of the range.
Baseline biomarkers: Elevated low-density lipoprotein, non-high-density lipoprotein cholesterol and homocysteine identified the responders in the only marker trial (Rahimi et al., 2019); normal baseline values predicted no change.
Pre-existing health conditions: Coronary artery disease was the setting in which marker responses occurred. Kidney stone history and treated hypotension shift the choice toward purified concentrate and away from whole-food loading.

Discontinuation & Cycling

Lifelong or short-term: No trial has run beyond four weeks, so extended use is untested. Betalains clear within 12 hours (Tesoriere et al., 2004), so any effect depends on continued intake.
Withdrawal effects: None reported. No trial documented rebound in pressure, lipids or performance after the washout periods, which ran from one to six weeks across the published crossovers.
Tapering: Not applicable. The crossover trials stopped supplementation abruptly between arms without incident (Montenegro et al., 2017), and no taper protocol exists in the literature.
Cycling for efficacy: No decay of effect has been demonstrated, so no cycling rationale exists. Sports protocols that load for six days before competition and stop afterwards reflect convenience, not tolerance management.
Marker of successful discontinuation: Beeturia resolves within a day of stopping: urinary excretion of intact pigment peaks about 3 hours after intake and falls with a 7.4-hour half-life (Frank et al., 2005).

Sourcing and Quality

Standardized betalain content: Labels should state milligrams of betalains, not milligrams of beetroot. The trial concentrate declares 12.5 mg betalains per 50 mg capsule (Van Hoorebeke et al., 2016); most beet powders declare neither figure.
Nitrate status: Products differ in whether nitrate has been removed. The performance trials used a nitrate- and sugar-free concentrate, while standard beet juice powders retain both (Milton-Laskibar et al., 2021).
Third-party testing: For competitive athletes, NSF Certified for Sport or Informed Sport marks confirm absence of banned substances. Neither certifies betalain content, which requires a batch certificate of analysis from the supplier.
Stability and processing: Betalains degrade with heat, light, oxygen and pH outside 4–6 (Sadowska-Bartosz & Bartosz, 2021). Cooked, pickled or long-stored products deliver far less pigment than their fresh-weight label implies.
Food sources ranked: Red beetroot is the densest common source, followed by prickly pear, red-fleshed dragon fruit, Swiss chard and amaranth leaves (Martinez et al., 2024). Each carries a different companion load of sugar, nitrate or oxalate.
Suppliers and their position: VDF FutureCeuticals supplies the standardized concentrate used in the published performance trials and is named as collaborator on the completed vascular trial (NCT06117007), so supplier and evidence base overlap.

Practical Considerations

Time to effect: Artery widening appears within 2–4 hours of a single dose and persists at 14 days (Cheok et al., 2022); performance trials dosed 120–150 minutes before exercise after six days of loading (Montenegro et al., 2017).
Dominant pitfall: Confusing betalains with beetroot nitrate. Both come from the same vegetable but act through unrelated pathways (Milton-Laskibar et al., 2021), and most beet marketing describes the nitrate effect while selling a pigment product.
Second pitfall: Buying cooked, pickled or heat-dried beet products and assuming the fresh-weight pigment content, when heat and acid have already destroyed much of it (Sadowska-Bartosz & Bartosz, 2021).
Third pitfall: Reading the appearance or absence of red urine as evidence of dose or absorption. It reflects gastric acidity and iron status instead (Watts et al., 1993).
Regulatory status: In the United States betalains are sold as dietary supplements and beet red is an exempt color additive under 21 CFR 73.40; in Europe beetroot red is the approved additive E162. No drug approval exists in any jurisdiction.
Cost and accessibility: Both the standardized concentrate and whole beetroot are inexpensive and widely available, and no institutional payer has a financial stake either way, since neither form is reimbursed by insurers or health systems.

Interaction with Foundational Habits

Sleep: Direction unknown — no completed trial has reported sleep outcomes. Sleep duration and stage distribution measured by wearable tracker are secondary endpoints of the 28-day vascular trial (NCT06117007), the first attempt at the question. The short clearance time makes an evening dose unlikely to disturb sleep.
Nutrition: Direct and destructive. Heat, light and acidity degrade betalains (Sadowska-Bartosz & Bartosz, 2021), so raw or gently cooked sources deliver more. Gastric acid also degrades them (Watts et al., 1993), so a heavy meal that delays stomach emptying may reduce intact delivery. Calcium alongside beet greens binds oxalate.
Exercise: Potentiating in the direction tested — concentrate taken 2–2.5 hours before endurance work improved time-trial performance and blunted muscle-damage markers across three crossover trials (Montenegro et al., 2017). Whether its antioxidant action blunts training adaptation, as high-dose vitamins C and E can, has not been examined.
Stress management: No direct interaction. No trial has measured cortisol or any stress-axis marker. The indirect link is inflammatory signaling, which betalains suppress in preclinical models (Fatima et al., 2026) but did not change in the one human cytokine measurement (Mumford et al., 2018).

Monitoring Protocol & Defining Success

Baseline testing establishes the markers that the human betalain trials actually moved, so that any change can be attributed rather than assumed. A lipid panel with non-high-density lipoprotein cholesterol, fasting homocysteine, fasting glucose with glycated hemoglobin, high-sensitivity C-reactive protein, seated blood pressure and a urinalysis form the core set. Iron studies and serum ferritin are added because red urine after beet ingestion tracks with iron status, and a baseline urinalysis documents that no blood is present before pigmented urine appears.

Ongoing monitoring follows the timescales seen in the trials: blood pressure at 2 and 4 weeks, the lipid, homocysteine and glucose panel at 8–12 weeks, then every 6–12 months while intake continues. Anyone using large amounts of beet greens or chard adds a 24-hour urinary oxalate measurement at 12 weeks.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Low-density lipoprotein cholesterol (LDL-C)	<100 mg/dL; <70 mg/dL with vascular disease	Changed meaningfully in the only lipid trial	12-hour fast. LDL-C is the cholesterol carried on low-density lipoprotein particles; conventional “normal” extends to 130 mg/dL
Non-high-density lipoprotein cholesterol	<130 mg/dL; <100 mg/dL with vascular disease	Captures every artery-damaging particle	Calculated as total minus high-density lipoprotein cholesterol, so no extra draw is needed
Homocysteine	5–8 µmol/L	Most responsive marker in the coronary trial	Fasting draw, plasma separated within one hour; conventional upper limit is 15 µmol/L
Fasting glucose	75–90 mg/dL	Tests the glycemic claim directly	8–12 hour fast, best paired with fasting insulin; conventional range extends to 99 mg/dL
Glycated hemoglobin (HbA1c)	4.8–5.3%	Integrates three months of glucose exposure	HbA1c is the fraction of hemoglobin carrying attached glucose; unreliable with anemia or recent blood loss. Conventional cutoff is 5.7%
Seated blood pressure	110–120 / 70–78 mmHg	Detects both the benefit and the additive hypotension risk	Home device, twice daily after five minutes seated; most informative in anyone already on pressure-lowering drugs
High-sensitivity C-reactive protein (hs-CRP)	<1.0 mg/L	Tests the anti-inflammatory claim	hs-CRP is a liver-produced protein that rises with inflammation; invalid within two weeks of infection or unusually hard training. Conventional reporting accepts up to 3.0 mg/L
Urinalysis with microscopy if positive	No blood, no protein	Establishes that red urine is pigment, not bleeding	Performed before the first dose. Microscopy distinguishes beeturia from hematuria (true blood in the urine)
Serum ferritin and transferrin saturation	Ferritin 50–150 ng/mL; saturation 25–35%	Beeturia frequency tracks iron status	Ferritin rises with inflammation, so it is read alongside hs-CRP; morning draw preferred for saturation. Conventional ranges are wider — ferritin accepted from about 15–30 ng/mL upward and saturation to 50%
24-hour urinary oxalate	<25 mg/24 h	Only for heavy beet-green or chard intake	Collected on a representative diet, not a low-oxalate one; conventional upper limit is 40–45 mg/24 h
Estimated glomerular filtration rate (eGFR) with creatinine	eGFR >90 mL/min/1.73 m²	Context for tolerating an oxalate load	eGFR is a calculated measure of kidney filtering capacity; creatinine is inflated by high muscle mass and by recent hard training. Conventional normal starts at 60 mL/min/1.73 m²

Qualitative markers worth tracking alongside the laboratory set:

Perceived exertion during steady-state work: fell roughly 15% at matched treadmill intensity in the running trial (Van Hoorebeke et al., 2016) but was unchanged in the triathlete trial (Montenegro et al., 2017), so it is a partial rather than a consistent signal
Next-day muscle soreness and fatigue: subjective soreness and fatigue scales did not change in the running trial (Van Hoorebeke et al., 2016) while fatigue scores improved in the triathlete trial (Montenegro et al., 2017), making this a weak signal
Urine and stool color: expected, harmless, and the earliest visible sign that pigment is passing through
Lightheadedness on standing: the practical signal of additive blood-pressure lowering in anyone on cardiovascular medication
Energy and cognitive clarity: untested for betalains specifically, useful only as a personal trend against a documented baseline

Emerging Research

Betalains and vascular function: NCT06117007 — completed crossover trial, 42 middle-aged adults with overweight, 25 mg betalains daily for 28 days; primary endpoint brachial flow-mediated dilation, with sleep and quality of life as secondaries. Run by King’s College London with the supplement manufacturer as collaborator; results unpublished.
Acute dosing for sprint performance: NCT06274385 — recruiting Drexel University crossover study in 10 recreationally active adults, testing a single 100 mg dose of betalain-rich concentrate 120 minutes before three repeated 30-second cycling sprints. Endpoints are peak power, average power and fatigue index.
Separating pigment from nitrate: NCT02949115 — phase 2 crossover in 15 adults aged 40–65 with overweight or obesity, including a nitrate-free beetroot juice arm alongside nitrate-only and placebo arms, which isolates the betalain contribution to post-meal vessel function. Registry status last reported as unknown.
Bioavailability as the limiting question: urinary recovery of intact betanin after red beet juice was 0.28% of the dose (Frank et al., 2005), while indicaxanthin recovery reached 76% (Tesoriere et al., 2004). Whether plasma levels reach those used in cell work is unresolved and could weaken mechanistic claims.
Longevity pathways in model organisms: pure betalains extended Caenorhabditis elegans lifespan by up to 16.8% through DAF-16/FOXO and SKN-1/Nrf2 signaling (Guerrero-Rubio et al., 2020), and red-beet pigments delayed amyloid-driven paralysis in the same organism (Imamura et al., 2022). No mammalian lifespan study has followed.
Industry funding as a limit: the concentrate used across the exercise trials comes from a single manufacturer (Van Hoorebeke et al., 2016), and that manufacturer collaborated on the completed vascular trial. Replication by groups without that tie would either strengthen or dissolve the performance claim.

Conclusion

Betalains are the red-violet and yellow-orange pigments of beetroot, prickly pear, chard and red dragon fruit, and they are among the few food pigments that have been isolated, concentrated and tested on their own. That separation matters, because beetroot’s best-known effect on blood flow comes from a different compound in the same vegetable, and stripping it out is what makes the pigment evidence interpretable.

What the human work supports is modest and specific. Repeated short trials in trained adults found small but consistent gains in endurance performance and faster recovery of muscle-damage markers. Single trials found better blood-vessel responsiveness, softer arteries, and improved cholesterol and a related blood marker in people with existing heart disease. Effects on blood pressure and inflammatory signals were inconsistent across those same trials, and the fall in blood sugar was too small to be called meaningful.

Everything beyond that — the anti-cancer, brain-protective, liver-protective, germ-killing and lifespan-extending findings that dominate the published literature — rests on cells, worms and rodents, not people. Safety in humans looks unremarkable over the weeks studied: the main documented effect is harmless red discoloration of urine and stool, which can be mistaken for bleeding.

Two limits shape how much weight the evidence carries. Sample sizes are small and follow-up rarely extends past a month. And much of the supplement testing has used one manufacturer’s product, with that manufacturer involved as funder or partner, so the evidence is not independent of the party that sells it.

Top - Benefits - Risks - Protocol

Betalains for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Endurance Exercise Performance and Recovery

Medium 🟩 🟩

Endothelial Function and Arterial Stiffness

Atherogenic Lipids and Homocysteine

Glycemic Markers

Low 🟩

Blood Pressure Reduction ⚠️ Conflicted

Reduction of Inflammatory Signaling ⚠️ Conflicted

Autonomic Balance and Heart-Rate Variability ⚠️ Conflicted

Speculative 🟨

Systemic Oxidative-Stress Reduction

Longevity-Pathway Activation

Anticancer Activity

Neuroprotection

Body-Fat Reduction

Liver Protection

Antimicrobial Activity

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Beeturia and Red-Pigmented Urine or Stool

Medium 🟥 🟥

Low 🟥

Additive Blood-Pressure Lowering ⚠️ Conflicted

Oxalate Burden from Whole-Food Sources

Nitrate Co-Exposure from Beetroot Vehicles

Allergic Reactions

Speculative 🟨

Interference with Drug-Metabolizing Enzymes

Unknown Long-Term Safety at Concentrated Doses

Hepatic Metal Accumulation from Whole-Beet Loading

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion